Pegintron and Heart attack - a phase IV clinical study of FDA data

Summary:

Heart attack is reported as a side effect among people who take Pegintron (peginterferon alfa-2b), especially for people who are male, 50-59 old, have been taking the drug for 1 - 6 months also take Rebetol, and have High blood pressure.

The phase IV clinical study analyzes which people have Heart attack when taking Pegintron. It is created by eHealthMe based on reports of 10,295 people who have side effects when taking Pegintron from the FDA, and is updated regularly.

What is Pegintron?

Pegintron has active ingredients of peginterferon alfa-2b. It is often used in hepatitis c. eHealthMe is studying from 10,326 Pegintron users. Check the latest studies of Pegintron.

What is Heart attack?

Heart attack is found to be associated with 2,479 drugs and 3,296 conditions by eHealthMe. Check the latest studies of Heart attack.

On Jul, 27, 2026

10,295 people reported to have side effects when taking Pegintron.
Among them, 12 people (0.12%) have Heart attack.

Among these 12 people:

How long have people been on Pegintron when they have Heart attack? *

What is the gender of people who have Heart attack when taking Pegintron? *

female: 33.33 %
male: 66.67 %

What is the age of people who have Heart attack when taking Pegintron? *

What are other drugs people take besides Pegintron? *

What are other side effects people have besides Heart attack? *

Anaemia (lack of blood): 3 people, 25.00%
Pain: 2 people, 16.67%
Loss Of Consciousness: 2 people, 16.67%
Fatigue (feeling of tiredness): 1 person, 8.33%
Depressed Mood: 1 person, 8.33%
Diabetic Neuropathy (neuropathic disorders that are associated with diabetes mellitus): 1 person, 8.33%
Dyspnea (difficult or laboured breathing): 1 person, 8.33%
Fainting (loss of consciousness and postural tone): 1 person, 8.33%
Fall: 1 person, 8.33%
Febrile Infection (infection with temperature rise): 1 person, 8.33%

What are the existing conditions these people have? *

High Blood Pressure: 2 people, 16.67%
Thyroid Diseases: 1 person, 8.33%
Relapsing Fever (bacterial infection characterized by recurring episodes of fever, headache, muscle and joint aches, and nausea): 1 person, 8.33%
Premenstrual Syndrome: 1 person, 8.33%
Malaise (a feeling of general discomfort or uneasiness): 1 person, 8.33%
Hepatic Cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue): 1 person, 8.33%
Diabetes: 1 person, 8.33%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 1 person, 8.33%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Pegintron and have Heart attack?

- Check whether Heart attack is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Pegintron:

Pegintron (10,326 reports)

Heart attack treatments and more:

Heart attack (266,145 reports)

Browse all side effects of Pegintron:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Heart attack:

Heart attack (2,479 drugs)

Browse all the conditions that are associated with Heart attack:

Heart attack (3,296 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on peginterferon alfa-2b (the active ingredients of Pegintron) and Pegintron (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.